Profile data is unavailable for this security.
About the company
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.
- Revenue in USD (TTM)0.00
- Net income in USD-42.29m
- Incorporated2011
- Employees11.00
- LocationSkye Bioscience Inc11250 EL CAMINO REAL, SUITE 100SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 410-0266
- Fax+1 (775) 782-2611
- Websitehttps://skyebioscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hillevax Inc | 0.00 | -156.27m | 89.61m | 90.00 | -- | 0.4329 | -- | -- | -3.38 | -3.38 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -55.47 | -- | -63.02 | -- | -- | -- | -- | -- | -- | -- | 0.1113 | -- | -- | -- | 22.68 | -- | -- | -- |
| bluebird bio Inc | 45.69m | -302.96m | 91.18m | 375.00 | -- | 0.6946 | -- | 2.00 | -2.44 | -2.44 | 0.3452 | 0.677 | 0.069 | 3.28 | -- | 121,837.30 | -45.76 | -34.75 | -66.24 | -40.84 | -22.60 | -124.35 | -663.09 | -5,770.41 | 0.8219 | -28.60 | 0.615 | -- | 720.04 | -11.58 | 8.00 | -- | -30.47 | -- |
| Metagenomi Inc | 55.93m | -75.00m | 91.79m | 228.00 | -- | 0.3407 | -- | 1.64 | -2.53 | -2.53 | 1.68 | 7.19 | 0.1408 | -- | 28.13 | 236,987.30 | -18.88 | -- | -22.14 | -- | -- | -- | -134.10 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Karyopharm Therapeutics Inc | 145.67m | -89.91m | 92.02m | 325.00 | -- | -- | -- | 0.6317 | -0.8356 | -0.8356 | 1.17 | -1.06 | 0.5692 | 1.62 | 4.15 | 448,209.20 | -35.14 | -53.02 | -45.50 | -65.85 | 96.04 | 97.18 | -61.72 | -125.15 | 3.56 | -7.37 | 2.00 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| CytomX Therapeutics Inc | 119.57m | 11.09m | 92.96m | 120.00 | 8.68 | -- | 7.16 | 0.7775 | 0.1371 | 0.1371 | 1.45 | -0.3997 | 0.6491 | -- | 51.12 | 996,408.30 | 6.02 | -21.53 | 26.34 | -32.32 | -- | -- | 9.27 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Coya Therapeutics Inc | 9.55m | -10.10m | 93.00m | 8.00 | -- | 2.64 | -- | 9.73 | -0.7726 | -0.7726 | 0.7589 | 2.32 | 0.3512 | -- | -- | 1,194,290.00 | -37.13 | -- | -40.92 | -- | -- | -- | -105.71 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Medicinova Inc | 1.00m | -8.16m | 93.19m | 13.00 | -- | 1.62 | -- | 93.19 | -0.1665 | -0.1665 | 0.0204 | 1.17 | 0.0155 | -- | -- | 76,923.08 | -12.65 | -15.36 | -13.19 | -15.90 | -- | -- | -816.49 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Ikena Oncology Inc | 1.84m | -66.71m | 93.41m | 18.00 | -- | 0.5776 | -- | 50.66 | -1.43 | -1.43 | 0.0393 | 2.96 | 0.0112 | -- | -- | 42,883.72 | -40.52 | -29.72 | -43.17 | -34.62 | -- | -- | -3,617.57 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Benitec Biopharma Inc | 7.00k | -21.69m | 93.80m | 18.00 | -- | 2.20 | -- | 13,400.13 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
| Oramed Pharmaceuticals, Inc. | 0.00 | 20.86m | 94.18m | 15.00 | 4.62 | 0.530 | 4.49 | -- | 0.4999 | 0.4999 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | 12.19 | -- | 12.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Immuneering Corp | 0.00 | -56.07m | 95.19m | 66.00 | -- | 1.44 | -- | -- | -1.91 | -1.91 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -55.52 | -- | -59.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -42.29m | 95.26m | 11.00 | -- | 1.21 | -- | -- | -3.91 | -3.91 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -94.50 | -232.67 | -129.40 | -- | -- | -- | -- | -- | -- | -323.10 | 0.0626 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Werewolf Therapeutics Inc | 9.28m | -53.73m | 95.71m | 45.00 | -- | 0.9201 | -- | 10.31 | -1.35 | -1.35 | 0.236 | 2.38 | 0.0548 | -- | 2.48 | 197,510.60 | -31.70 | -- | -34.39 | -- | -- | -- | -578.80 | -- | -- | -- | 0.1948 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Clearside Biomedical Inc | 7.52m | -33.46m | 97.92m | 30.00 | -- | -- | -- | 13.01 | -0.497 | -0.497 | 0.1119 | -0.3785 | 0.2058 | -- | 59.01 | 250,800.00 | -91.51 | -63.57 | -107.97 | -81.77 | 95.06 | -- | -444.66 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
| Boundless Bio Inc | 0.00 | -57.72m | 97.92m | 72.00 | -- | 0.5463 | -- | -- | -2.60 | -2.60 | 0.00 | 8.05 | 0.00 | -- | -- | 0.00 | -33.64 | -- | -35.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
Data as of Sep 23 2024. Currency figures normalised to Skye Bioscience Inc's reporting currency: US Dollar USD
1.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 30 Jun 2024 | 370.18k | 1.32% |
| The Bank of New York Mellon Corp. (Investment Management)as of 30 Jun 2024 | 42.67k | 0.15% |
| AdvisorShares Investments LLCas of 30 Jun 2024 | 26.00k | 0.09% |
| State Street Global Advisors Trust Co.as of 04 Jul 2024 | 23.80k | 0.09% |
| Teachers Advisors LLCas of 30 Jun 2024 | 23.39k | 0.08% |
| RhumbLine Advisers LPas of 30 Jun 2024 | 19.75k | 0.07% |
| Mellon Investments Corp.as of 30 Jun 2024 | 16.11k | 0.06% |
| New York State Common Retirement Fundas of 30 Jun 2024 | 13.80k | 0.05% |
| Global X Management Co. LLCas of 03 Jul 2024 | 9.46k | 0.03% |
| State Teachers Retirement System of Ohioas of 30 Jun 2024 | 3.20k | 0.01% |
More ▼
Data from 30 Jun 2024 - 08 Aug 2024Source: FactSet Research Systems Inc.
